Surgery Partners, Inc. (NASDAQ:SGRY) is a healthcare services holding company that specializes in providing surgical and related ancillary care solutions to support its patients and physicians. The company operates through three business segments, namely Surgical Facility Services, Ancillary Services, and Optical Services.
Recently, Bloomberg.com reported that shares of Surgery Partners have received a consensus recommendation of “Moderate Buy” from twelve analysts covering the stock. Out of these twelve analysts, two have rated the stock with a hold recommendation while seven have given it a buy recommendation. This indicates a positive outlook for the company and reflects the strong potential growth prospects of its business operations.
Moreover, the recent activities of some institutional investors also suggest that they see value in investing in Surgery Partners. Notably, Ellevest Inc., PNC Financial Services Group Inc., Nisa Investment Advisors LLC, Tower Research Capital LLC TRC, and Signaturefd LLC have acquired or increased their holdings in shares of Surgery Partners in recent months.
Ellevest Inc. has increased its stake by 123.8% during the first quarter and now holds 817 shares worth $28,000 after purchasing an additional 452 shares. Similarly, PNC Financial Services Group Inc. has acquired an additional 476 shares during the last quarter and now possesses 1,033 shares worth $29,000.
Nisa Investment Advisors LLC upped its investment by 284.7% in the first quarter when it purchased another 780 shares amounting to a total holding of 1,054 shares worth $36,000.
Tower Research Capital LLC TRC grew its stake by 187.1% during Q1 when it added another 801 shares taking its total ownership to 1,229 shares worth $42,000.
Finally, Signaturefd LLC bought a new stake worth $43k in SGRY stock back in Q3-2020 further indicating investor confidence towards Surgery Partners.
Taken together, these measures suggest that investors anticipate profitable growth from the company in the future and that it is likely to be a fruitful investment option. Additionally, the average 12-month price target of $44.09 among brokerages that have issued ratings on the stock in the last year should further buttress investor confidence in this company’s stock. Therefore, it would seem wise for potential investors to consider adding SGRY shares to their portfolios given its strong potential for growth.
[bs_slider_forecast ticker=”SGRY”]
Surgery Partners Inc: Examining Performance, Analyst Reports, and Recent Insider Transactions
Surgery Partners, Inc. has recently become the talk of the town in the healthcare industry. A healthcare services holding company, it provides surgical and ancillary care solutions for its patients and physicians. The company operates through three business segments: Surgical Facility Services, Ancillary Services, and Optical Services. Shares of NASDAQ SGRY opened at $39.26 on Tuesday following a high of $41.80 over the past fifty-two weeks.
Several brokerages have issued reports on SGRY lately with mixed opinions on its performance. JPMorgan Chase & Co, for instance, changed their price target from $45.00 to a target of $40.00 and gave it a “neutral” rating while Citigroup increased their price target to $47.00 from previous target figure of $40.00 on May 2nd this year.
Moreover, StockNews.com just began its coverage on Surgery Partners in a report published on May 18th with a “hold” rating while Benchmark reissued its “buy” rating along with issuing a price target of $47.00 earlier in March this year.
In relation to latest stock news, insider Bradley R. Owens recently sold 7,191 shares at an average cost of $36.31 equating $261,105 overall value in only one transaction that took place on May 17th this year further he now owns 74,189 shares worth approximately around $2,693,802.The CEO Jason Eric Evans also later sold his shares amounting to a total transactional value of over two hundred thousand USD at the close-out part of March month.
The firm’s market cap is currently estimated at $4.97 billion while beta equals out to be 2..75.Company’s quick ratio is 1%%-68 while current equals out to be –1%%%830 .Debt-to-equity ratio is quite subpar as well currently standing at 0.86.
Finally, Surgery Partners (NASDAQ:SGRY) has successfully exceeded its forecasted earnings sum for last fiscal quarter. The firm issued its quarterly earning report back on May 1st wherein the company released positive financial statements.Afterward which a lot of analysts believe it will attract more investors towards SGRY.
In this respect, the company earned $0.05 per share during the period compared to estimate of -$0.04, thereby having a net margin of -3.51%. Additionally the firm had an impressive $666.20 million in revenue during Q1 FY2017 surmounting to previous analyst consensus estimates of $644.16M.
It will be interesting to keep track of how this medical firm progresses in coming months across stock market infrastructure and if any new news is thus projected by insiders for investors quarters to come.